F. Mardjuadi

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

Antonio Jimeno, Jean‐Pascal Machiels, Lori J. Wirth et al. · Cancer · 2016 · 45 citations · Full text

Medicine, Oncology, Pharmacology +16

Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer

F. Mardjuadi, Javier Carrasco, Jean-Charles Coche et al. · Targeted Oncology · 2014 · 20 citations · Full text

Medicine, Oncology, Pharmacology +12

A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors.

Emiliano Calvo, Marta Gil-Martín, Jean‐Pascal Machiels et al. · Journal of Clinical Oncology · 2014 · 15 citations

Medicine, Pharmacokinetics, Pharmacology +14

Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.

Tony Mok, Diego Cortinovis, Margarita Majem et al. · Journal of Clinical Oncology · 2022 · 13 citations

Medicine, Oncology, Pharmacology +17

994P Efficacy and safety of capmatinib plus spartalizumab in treatment-naïve patients with advanced NSCLC harboring MET exon 14 skipping mutation

Jennifer Moriatis Wolf, Rebecca S. Heist, T.M. Kim et al. · Annals of Oncology · 2022 · 10 citations

Medicine, Oncology, Pharmacology +7